Literature DB >> 17215425

Restrictions on antidepressant medications for children: a review of Medicaid policy.

Michael A Fischer1, Amber D Servi, Jennifer M Polinski, Philip S Wang.   

Abstract

OBJECTIVE: This study evaluated Medicaid's prior-authorization policies restricting the prescribing of antidepressant medications for children.
METHODS: Medicaid program prior-authorization policies for antidepressant medications were obtained for all available states. All criteria needed for authorization were recorded, with a focus on policies that applied specifically to children.
RESULTS: Data from 49 states and the District of Columbia revealed that 30 states (60%) required prior authorization for antidepressants, of which eight (27%) made specific provisions for children. These provisions varied across states. In most states fluoxetine could be prescribed for children with minimal restrictions, and two states had prior-authorization policies that strongly encouraged pediatric patients to use fluoxetine. State policies regarding other selective serotonin reuptake inhibitors varied widely.
CONCLUSIONS: Although relatively few states included provisions for children in prior-authorization requirements for antidepressants, in states that did, the policies implemented varied widely. These findings raise important questions about the rational development of prescription drug reimbursement policy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17215425     DOI: 10.1176/ps.2007.58.1.135

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  2 in total

1.  The effects of prior authorization policies on medicaid-enrolled children's use of antipsychotic medications: evidence from two mid-Atlantic states.

Authors:  Bradley D Stein; Emily Leckman-Westin; Edward Okeke; Deborah M Scharf; Mark Sorbero; Qingxian Chen; Ka Ho Brian Chor; Molly Finnerty; Jennifer P Wisdom
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-08-21       Impact factor: 2.576

2.  Prior authorization for biologic disease-modifying antirheumatic drugs: a description of US Medicaid programs.

Authors:  Michael A Fischer; Jennifer M Polinski; Amber D Servi; Jessica Agnew-Blais; Liljana Kaci; Daniel H Solomon
Journal:  Arthritis Rheum       Date:  2008-11-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.